New Transcatheter Aortic Valve Implantation (TAVI) Guidewire

New Transcatheter Aortic Valve Implantation (TAVI) Guidewire: a prospective first-in-man single-centre open-label non-randomised feasibility study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN29111908

Enrollment

Registered

2010-06-18

Start date

2010-06-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic stenosis, cardiovascular disease Circulatory System Complications and ill-defined descriptions of heart disease

Interventions

All consenting patients will be allocated to the normal standard of treatment for TAV implantation including the follow-up. The only difference is the used of the new guidewire during implantation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for transcatheter aortic valve implantation (TAVI) 2. Male and female, aged 18 - 100 years

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Technical success of the TAVI procedure, measured at end of procedure	—

Secondary

Measure	Time frame
Guidewire performance, measured at end of procedure	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026